Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer. 1986

G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux

Seventy-seven patients with advanced gastric carcinoma were prospectively randomized to receive 5-FU and carmustine (FB) with or without doxorubicin (FAB). Thirty-five patients were evaluable for response. Neither the response rates (partial remission, 11% for FB and 24% for FAB) nor survival times (median, 4.0 months for FB and 5.5 months for FAB) were statistically different. The median survival of patients with partial remission (7.8 months) and those with no change (7.4 months) was significantly prolonged compared to patients with progressive disease (4.5 months). The side effects of both regimens after the first treatment cycle (except alopecia in FAB) were low. After the second cycle more pronounced myelosuppression in the FAB arm was observed.

UI MeSH Term Description Entries
D007813 Laparotomy Incision into the side of the abdomen between the ribs and pelvis. Minilaparotomy,Laparotomies,Minilaparotomies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux
October 1984, Cancer treatment reports,
G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux
October 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux
January 1990, Acta oncologica (Stockholm, Sweden),
G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux
June 1993, Cancer,
G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux
January 1985, Oncology,
G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux
April 1986, Cancer treatment reports,
G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux
December 1982, Cancer treatment reports,
G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux
January 1980, Cancer treatment reports,
G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux
January 1986, Oncology,
G Schnitzler, and W Queisser, and M E Heim, and H König, and R Katz, and D Fritze, and R Herrmann, and H Arnold, and H Henss, and F A Trux
January 1981, Cancer treatment reports,
Copied contents to your clipboard!